HIV Suppression Falls as Discrimination Rises in Europe

Recent data indicates a concerning trend across the WHO European Region: while progress has been made in HIV treatment access, HIV suppression rates are declining in some areas, coinciding with rising levels of stigma and discrimination. This combination threatens to undermine years of public health advancement, particularly among key populations who face systemic barriers to care.

HIV stigma remains a significant obstacle throughout Central and Eastern Europe, where discriminatory attitudes in healthcare, community, and legislative settings deter individuals from seeking testing and treatment. Fear of confidentiality breaches and anticipated judgment from healthcare providers prevent many from engaging with HIV services, leading to delayed diagnosis and poorer health outcomes. These challenges are compounded by punitive laws that criminalize HIV transmission, same-sex relations, drug leverage, and sex work, further marginalizing vulnerable groups.

Evidence shows that stigma directly impacts the HIV care continuum. Individuals experiencing discrimination are less likely to initiate or adhere to antiretroviral therapy, reducing the likelihood of achieving viral suppression. When viral suppression falls, not only does individual health deteriorate, but the risk of HIV transmission increases, undermining prevention efforts such as Undetectable = Untransmittable (U=U).

To reverse this trend, experts emphasize the demand for integrated strategies that combine expanded access to testing and treatment with robust anti-stigma interventions. Emergency room opt-out HIV testing has shown promise in reaching populations that avoid traditional healthcare settings due to stigma. Training healthcare workers in non-discriminatory care, enforcing confidentiality protections, and reforming discriminatory legislation are critical steps toward improving engagement and outcomes.

Addressing HIV-related discrimination is not only a matter of equity but also a public health necessity. As long as stigma persists, efforts to achieve the 95-95-95 targets—where 95% of people living with HIV know their status, 95% of those diagnosed receive treatment, and 95% of those on treatment are virally suppressed—will remain out of reach in many parts of Europe.

Moving forward, sustained investment in stigma reduction programs, community-led initiatives, and policy reform will be essential to ensure that advances in HIV treatment translate into real-world health improvements for all.